Health and Healthcare

AstraZeneca : AZN

All AstraZeneca Articles

221 Articles

Paul Ausick | May 5, 2014 at 8:00 AM EDT

Pfizer Earnings Confirm Reasons for AstraZeneca Offer

Drug giant Pfizer reported better-than-expected first-quarter 2014 earnings before markets opened Monday morning, but revenues fell short. Shares traded lower…

Paul Ausick | May 2, 2014 at 8:55 AM EDT

AstraZeneca Declares Pfizer Bid ‘Inadequate’

British drug maker AstraZeneca once again rejected a takeover bid from U.S. pharmaceutical giant Pfizer, this one worth $106 billion…

Jon C. Ogg | Apr 22, 2014 at 8:35 AM EDT

Top Analyst Upgrades and Downgrades: AMD, ARM, Barrick, Netflix, Teva, Valero and More

These are the top analyst upgrades, downgrades and initiations for Tuesday, April 22, 2014. They include AMD, ARM Holdings, Barrick…

Jon C. Ogg | Apr 21, 2014 at 1:25 PM EDT

What a Combined Pfizer and AstraZeneca Would Look Like, and Face

ThinkstockIt is not that common that you hear about mergers in the $50 billion range. But what about when you…

Jon C. Ogg | Mar 3, 2014 at 8:20 AM EST

Top Analyst Upgrades and Downgrades: Apple, MarkWest, NII Holdings, RF Micro, SodaStream and More

These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Monday, March 3, 2014.…

Jon C. Ogg | Nov 19, 2013 at 12:30 PM EST

Horizon Pharma Deal Ramps Up Profitability Timeline

ThinkstockHorizon Pharma Inc. (NASDAQ: HZNP) is having a stellar day after breaking news that it entered into a pact with…

Douglas A. McIntyre | Oct 2, 2013 at 6:30 AM EDT

Big Pharma and 100,000 Jobs at Risk

ThinkstockMerck & Co. (NYSE: MRK) announced it would rid itself of 8,500 workers, many of whom work in the big…

Lee Jackson | Sep 16, 2013 at 8:45 AM EDT

Wall Street Sees Big Biotech Making Tens of Billions in Two Critical Areas

ThinkstockInvestors make big money in biotechnology stocks when they focus on areas that cut across a wide swath of the…

Trey Thoelcke | Sep 13, 2013 at 8:50 AM EDT

UBS Offers Eight Well-Known International Large Cap Dividend Ruler Stocks

ThinkstockWith yields on 10-year Treasury bonds up nearly 1.5% since early May and briefly touching 3.0% last week, the impact…

Jon C. Ogg | Aug 15, 2013 at 8:30 AM EDT

Top Analyst Upgrades and Downgrades: Carnival, Intel, Micron, Pulte and More

Jon OggInvestors are on the hunt for solid research ideas now that stocks have pulled back a bit. 24/7 Wall…

Paul Ausick | Jul 2, 2013 at 7:35 AM EDT

Drugmakers Pfizer, Bayer, Novartis May Join Bidding for Onyx

ThinkstockAlthough Amgen Inc.’s (NASDAQ: AMGN) $10 billion offer for Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) was unsolicited and not exactly a…

Jon C. Ogg | Jun 17, 2013 at 8:10 AM EDT

UBS Dividend Ruler Stocks Combine Solid Yield and Growth Prospects

ThinkstockOver the past five weeks, the 10-year Treasury bond yield has increased by over one-half of one percent from 1.66%…

Paul Ausick | Jun 4, 2013 at 4:06 PM EDT

Closing Bell for Tuesday on Wall Street: Markets Open Higher, Sink Later

U.S. equity markets opened slightly higher this morning but lost steam in the afternoon to finish with a loss for…

Jon C. Ogg | May 9, 2013 at 8:35 AM EDT

UBS Offers Global Dividend Ruler Stocks to Buy: Total, Teva, TD and More

ThinkstockTotal return is always the name of the game when it comes to investing success. Stocks that pay dividends on…

Jon C. Ogg | May 6, 2013 at 10:45 AM EDT

The Top Seven Drugs with U.S. Quarterly Sales Over $1 Billion

ThinkstockThe world of pharmaceuticals may have faced a patent cliff in recent years, but brand name drugs are still generating…

1 … 8 9 10 11 12 … 15

AstraZeneca : AZN

All AstraZeneca Articles

Pfizer Earnings Confirm Reasons for AstraZeneca Offer

AstraZeneca Declares Pfizer Bid ‘Inadequate’

Top Analyst Upgrades and Downgrades: AMD, ARM, Barrick, Netflix, Teva, Valero and More

What a Combined Pfizer and AstraZeneca Would Look Like, and Face

Top Analyst Upgrades and Downgrades: Apple, MarkWest, NII Holdings, RF Micro, SodaStream and More

Horizon Pharma Deal Ramps Up Profitability Timeline

Big Pharma and 100,000 Jobs at Risk

Wall Street Sees Big Biotech Making Tens of Billions in Two Critical Areas

UBS Offers Eight Well-Known International Large Cap Dividend Ruler Stocks

Top Analyst Upgrades and Downgrades: Carnival, Intel, Micron, Pulte and More

Drugmakers Pfizer, Bayer, Novartis May Join Bidding for Onyx

UBS Dividend Ruler Stocks Combine Solid Yield and Growth Prospects

Closing Bell for Tuesday on Wall Street: Markets Open Higher, Sink Later

UBS Offers Global Dividend Ruler Stocks to Buy: Total, Teva, TD and More

The Top Seven Drugs with U.S. Quarterly Sales Over $1 Billion

Avoid Zillow: This Infrastructure Redirect Is a “No-Brainer” Buy as the Housing Market Stalls

History Says This Unstoppable Dow Juggernaut Is a No-Brainer Buy Right Now

Lucid Stock Is Deeply Oversold and We See 45% Gains Ahead

The $1,847 Monthly Survivor Benefit Most Widows Leave on the Table by Filing at the Wrong Age

The West's Home Prices Just Fell 1.4% While the Rest of America Climbed. Here's Why.

Avoid Zillow: This Infrastructure Redirect Is a “No-Brainer” Buy as the Housing Market Stalls

History Says This Unstoppable Dow Juggernaut Is a No-Brainer Buy Right Now

AstraZeneca : AZN

All AstraZeneca Articles

Pfizer Earnings Confirm Reasons for AstraZeneca Offer

AstraZeneca Declares Pfizer Bid ‘Inadequate’

Top Analyst Upgrades and Downgrades: AMD, ARM, Barrick, Netflix, Teva, Valero and More

What a Combined Pfizer and AstraZeneca Would Look Like, and Face

Top Analyst Upgrades and Downgrades: Apple, MarkWest, NII Holdings, RF Micro, SodaStream and More

Horizon Pharma Deal Ramps Up Profitability Timeline

Big Pharma and 100,000 Jobs at Risk

Wall Street Sees Big Biotech Making Tens of Billions in Two Critical Areas

UBS Offers Eight Well-Known International Large Cap Dividend Ruler Stocks

Top Analyst Upgrades and Downgrades: Carnival, Intel, Micron, Pulte and More

Drugmakers Pfizer, Bayer, Novartis May Join Bidding for Onyx

UBS Dividend Ruler Stocks Combine Solid Yield and Growth Prospects

Closing Bell for Tuesday on Wall Street: Markets Open Higher, Sink Later

UBS Offers Global Dividend Ruler Stocks to Buy: Total, Teva, TD and More

The Top Seven Drugs with U.S. Quarterly Sales Over $1 Billion

Avoid Zillow: This Infrastructure Redirect Is a “No-Brainer” Buy as the Housing Market Stalls

History Says This Unstoppable Dow Juggernaut Is a No-Brainer Buy Right Now

Lucid Stock Is Deeply Oversold and We See 45% Gains Ahead

Featured Reads

The $1,847 Monthly Survivor Benefit Most Widows Leave on the Table by Filing at the Wrong Age

The West's Home Prices Just Fell 1.4% While the Rest of America Climbed. Here's Why.